JP2017520531A5 - - Google Patents

Download PDF

Info

Publication number
JP2017520531A5
JP2017520531A5 JP2016568950A JP2016568950A JP2017520531A5 JP 2017520531 A5 JP2017520531 A5 JP 2017520531A5 JP 2016568950 A JP2016568950 A JP 2016568950A JP 2016568950 A JP2016568950 A JP 2016568950A JP 2017520531 A5 JP2017520531 A5 JP 2017520531A5
Authority
JP
Japan
Prior art keywords
fragment
antibody
hydrophobic interaction
interaction chromatography
ultrafiltration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016568950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017520531A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/001643 external-priority patent/WO2015186004A2/en
Publication of JP2017520531A publication Critical patent/JP2017520531A/ja
Publication of JP2017520531A5 publication Critical patent/JP2017520531A5/ja
Pending legal-status Critical Current

Links

JP2016568950A 2014-06-02 2015-06-02 Fc断片の産生 Pending JP2017520531A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462006584P 2014-06-02 2014-06-02
US62/006,584 2014-06-02
PCT/IB2015/001643 WO2015186004A2 (en) 2014-06-02 2015-06-02 Production of fc fragments

Publications (2)

Publication Number Publication Date
JP2017520531A JP2017520531A (ja) 2017-07-27
JP2017520531A5 true JP2017520531A5 (https=) 2018-07-12

Family

ID=54337822

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016568950A Pending JP2017520531A (ja) 2014-06-02 2015-06-02 Fc断片の産生

Country Status (12)

Country Link
US (1) US20170129966A1 (https=)
EP (1) EP3149030A2 (https=)
JP (1) JP2017520531A (https=)
KR (1) KR20170040132A (https=)
CN (1) CN106573973A (https=)
AR (1) AR100716A1 (https=)
AU (1) AU2015270152A1 (https=)
BR (1) BR112016028182A2 (https=)
CA (1) CA2950241A1 (https=)
IL (1) IL249274A0 (https=)
MX (1) MX2016015893A (https=)
WO (1) WO2015186004A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140093603A (ko) 2010-12-30 2014-07-28 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 병원체 불활성화제로서의 글리콜
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
EP3594231A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
MX384222B (es) 2013-07-05 2025-03-14 Lab Francais Du Fractionnement Matriz de cromatografia de afinidad.
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
EP3710474A1 (en) * 2017-11-14 2020-09-23 Bio-Sourcing S.A. Antibody purification
WO2019116096A1 (en) * 2017-12-15 2019-06-20 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Production of fc fragments
FR3075200B1 (fr) * 2017-12-15 2022-12-23 Lab Francais Du Fractionnement Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc
CN111902720B (zh) 2018-03-21 2025-02-07 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
CN110669134A (zh) * 2019-10-15 2020-01-10 广东菲鹏生物有限公司 IgM-FC片段、IgM-FC抗体及制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US6268487B1 (en) * 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
TWI372763B (en) * 2005-06-17 2012-09-21 Wyeth Llc Methods of purifying anti a beta antibodies
MX2008012843A (es) * 2006-04-05 2009-01-19 Univ Rockefeller Polipeptidos con propiedades antiinflamatorias aumentadas y citotoxicas reducidas y metodos relacionados.
CN105131127B (zh) 2007-05-30 2018-09-07 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
EP2170390B1 (en) * 2007-06-14 2018-11-07 Biogen MA Inc. Natalizumab antibody formulations
JP2013516500A (ja) 2010-01-11 2013-05-13 ヒールオア・リミテッド 炎症性疾患および障害を治療するための方法
WO2013021279A2 (en) * 2011-08-10 2013-02-14 Lfb Biotechnologies Highly galactosylated antibodies
GB201115665D0 (en) 2011-09-09 2011-10-26 Univ Leuven Kath Autoimmune and inflammatory disorder therapy

Similar Documents

Publication Publication Date Title
JP2017520531A5 (https=)
JP2012143232A5 (https=)
JP2015532096A5 (https=)
WO2012009544A3 (en) Domain insertion immunoglobulin
MX2022001831A (es) Anticuerpos terapeuticos y sus usos.
PE20220392A1 (es) Moleculas de union a claudina-6 y usos de las mismas
HK1254357A1 (zh) 特异性针对过度磷酸化t蛋白的抗体及其使用方法
WO2012006596A3 (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
EP2522724A4 (en) POLYPEPTIDE MODIFYING METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
MX2016001601A (es) Separacion de anticuerpos biespecificos y subproductos de produccion de anticuerpos biespecificos utilizando cromatografia de hidroxiapatita.
JP2013538057A5 (https=)
BR112015018203A2 (pt) Anti-corpos biespecíficos anti-tnf-anti-il-17
JP2018536393A5 (https=)
WO2013177115A3 (en) Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
JP2012116856A5 (https=)
WO2017015619A8 (en) Antibodies to coagulation factor xia and uses thereof
JP2018505681A5 (https=)
PE20191548A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
AR099625A1 (es) Anticuerpos de il-21
JP2017505620A5 (https=)
RU2019111862A (ru) Новые антитела против фактора xi и их применения
EA202191658A1 (ru) Антитела против фактора c2b комплемента человека и способы применения
EA202192907A1 (ru) Моноклональное антитело, которое специфически связывается с gitr
BR112017027702A2 (pt) anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2)
MX2019014105A (es) Composiciones biofarmaceuticas y metodos relacionados.